Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Capecitabine
Xeloda
Routinely available
Local application
29/03/2023
Indication
Treatment of early breast cancer following neoadjuvant anthracycline and/or taxane based chemotherapy with residual disease in breast or axillary lymph nodes at time of surgery.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with local guidance for prescribing
Formulation
-
Comments
-